Table 2.
Univariate and multivariable Cox regression analyses of CIP2A expression levels and survival rates
| |
Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | P- value | HR | 95% CI | P- value |
| |
|
Overall survival |
|
|
|
|
| CIP2A expression (High vs. Low) |
2.13 |
1.18-3.84 |
0.012 |
1.85 |
1.02-3.35 |
0.042 |
| TNM stage (III-IV vs. I-II) |
3.16 |
1.57-6.39 |
0.001 |
2.87 |
1.42-5.82 |
0.003 |
| Sex (Male vs. Female) |
1.57 |
0.86-2.87 |
0.146 |
|
|
|
| Age (>45 years vs. ≤45 years) |
1.43 |
0.87-2.34 |
0.155 |
|
|
|
| WHO type (III vs. I + II) |
0.81 |
0.26-2.58 |
0.722 |
|
|
|
| VCA-IgA (≥1:80 vs. < 1:80) |
1.80 |
0.78-4.17 |
0.168 |
|
|
|
| EA-IgA (≥1:10 vs. < 1:10) |
1.19 |
0.66-2.15 |
0.555 |
|
|
|
| |
|
Disease-free survival |
|
|
|
|
| CIP2A expression (High vs. Low) |
1.92 |
1.16-3.17 |
0.011 |
1.70 |
1.03-2.82 |
0.039 |
| TNM stage (III-IV vs. I-II) |
2.87 |
1.59-5.17 |
<0.001 |
2.59 |
1.43-4.69 |
0.002 |
| Sex (Male vs. Female) |
1.57 |
0.93-2.68 |
0.094 |
|
|
|
| Age (>45 years vs. ≤45 years) |
1.25 |
0.82-1.93 |
0.301 |
|
|
|
| WHO type (III vs. I + II) |
0.78 |
0.29-2.12 |
0.622 |
|
|
|
| VCA-IgA (≥1:80 vs. < 1:80) |
2.06 |
0.95-4.46 |
0.068 |
|
|
|
| EA-IgA (≥1:10 vs. < 1:10) | 1.44 | 0.84-2.48 | 0.190 | |||